El Mesbahi Omar, Brahmi Sami Aziz, Akasbi Yousra, El Mrabet Fatima Zahra, Touyar Anas, Ossaden Abdelmalek, Znati Kaoutar, Maazaz Khalid, Amarti Affaf, Tizniti Siham, Taleb Khalid Ait, Ibrahimi Adil
Medical Oncology Department, Hassan II University Hospital, Fez, Morocco.
J Med Case Rep. 2011 May 21;5:197. doi: 10.1186/1752-1947-5-197.
Gastrointestinal stromal tumors are a rare neoplasm exhibiting, in most cases, mutations of c-kit. Imatinib mesylate is the standard treatment for patients who have advanced gastrointestinal stromal tumors. Although the response rate in patients treated with imatinib mesylate in prospective clinical studies is above 50%, a complete response is very rare. We report the case of a patient with a gastric gastrointestinal stromal tumor who had a pathological complete response after neoadjuvant treatment with imatinib mesylate.
We report the case of a 54-year-old Arab woman with a gastrointestinal stromal tumor who had a pathological complete response after neoadjuvant treatment with imatinib mesylate.
The pathological examination of our patient documented a complete pathological response after imatinib therapy. Recently, it has been confirmed that the kinase genotype of KIT and platelet-derived growth factor receptor α can accurately predict a good response to imatinib mesylate therapy. We propose that this patient had a mutation conferring high sensitivity to imatinib mesylate.
胃肠道间质瘤是一种罕见的肿瘤，在大多数情况下表现为c-kit基因突变。甲磺酸伊马替尼是晚期胃肠道间质瘤患者的标准治疗药物。尽管在前瞻性临床研究中接受甲磺酸伊马替尼治疗的患者缓解率超过50%，但完全缓解非常罕见。我们报告了1例胃胃肠道间质瘤患者，在接受甲磺酸伊马替尼新辅助治疗后获得病理完全缓解的病例。
我们报告1例54岁患有胃肠道间质瘤的阿拉伯女性患者，在接受甲磺酸伊马替尼新辅助治疗后获得病理完全缓解。
对我们患者的病理检查记录了伊马替尼治疗后的完全病理缓解。最近，已证实KIT和血小板衍生生长因子受体α的激酶基因型可准确预测对甲磺酸伊马替尼治疗的良好反应。我们认为该患者存在对甲磺酸伊马替尼高度敏感的突变。
